WHO rules have to have manufacturers to carry out a continual chance management procedure for sterility test isolators, including frequent risk assessments and the development of possibility-based Handle methods. Manufacturers planning to apply these procedures have to deliver strong validation data to display their equivalence to pharmacopoeial solutions. Keep waiting for link from Forum Profiles (6)